Results 231 to 240 of about 976,226 (308)

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli   +3 more
wiley   +1 more source

Synthesis and evaluation of vanillin-based sulfonates as potent α-glucosidase inhibitors through in vitro, in vivo, and in silico approaches. [PDF]

open access: yesSci Rep
Essid M   +9 more
europepmc   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9101-9111, October 2026.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda   +4 more
wiley   +1 more source

Exploring the α-Glucosidase Inhibitory Activity of Bioactive Compounds from <i>Persicaria odorata</i> (Lour.) Extracts via Integrated In Vitro and In Silico Studies. [PDF]

open access: yesInt J Mol Sci
Subhan M   +9 more
europepmc   +1 more source

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9633-9643, October 2026.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain   +15 more
wiley   +1 more source

Transcriptomic and proteomic signatures underlying nymphal adaptation and foam production in the forage pest Mahanarva spectabilis

open access: yesInsect Molecular Biology, Volume 35, Issue 5, Page 556-575, October 2026.
RNA‐seq and Batelli gland proteomics of fifth‐instar Mahanarva spectabilis nymphs reveal transcripts and proteins associated with xylem feeding, foam production and environmental interaction. Functional annotation identified genes involved in osmoregulation, detoxification, chemosensation and stress responses, while proteomic analysis confirmed ...
Monique da Silva Bonjour   +8 more
wiley   +1 more source

Enzyme@Silicone: A Versatile Combo for Robust Synthetic Biocatalysis?

open access: yesAdvanced Synthesis &Catalysis, Volume 368, Issue 17, 1 September 2026.
Silicone‐based polymers are versatile materials for enzyme immobilization, offering unique advantages such as chemical inertness, thermal stability, and tunable morphology. This review highlights their applications in synthetic biocatalysis, from batch to continuous processes, and addresses key challenges such as mass transport limitations and ...
Marion B. Ansorge‐Schumacher
wiley   +1 more source

Home - About - Disclaimer - Privacy